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Abstract
The current interest in epigenetic priming is underpinned by the belief that remodelling of the epigenetic landscape will
sensitise tumours to subsequent therapy. In this pre-clinical study, paediatric AML cells expanded in culture and primary
AML xenografts were treated with decitabine, a DNA demethylating agent, and cytarabine, a frontline cytotoxic agent used
in the treatment of AML, either alone or in combination. Sequential treatment with decitabine and cytarabine was found to
be more effective in reducing tumour burden than treatment with cytarabine alone suggesting that the sequential delivery
of these agents may a have real clinical advantage in the treatment of paediatric AML. However we found no evidence to
suggest that this outcome was dependent on priming with a hypomethylating agent, as the benefits observed were
independent of the order in which these drugs were administered.
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Introduction
Survival rates for patients with acute myeloid leukemia (AML)
remain inadequate with an overall survival of 40–45% reported in
younger adults, and 63% in under 16 year olds who have a relapse
rate of 35% [1]. While both anthracyclines and cytarabine (Ara-C)
provide an effective backbone for most AML treatment protocols,
new therapies offering a survival advantage over current standard
treatments have been elusive, with the possible exception of the
calicheamicin-conjugated antibody gemtuzumab ozogamicin [2].
Increasing interest in targeting epigenetic pathways has led to
multiple studies of DNA demethylating agents, including decita-
bine (DAC) administered in low dose regimens [3–5]. DAC is a
nucleoside analog believed to have multiple distinct mechanisms of
action, including; activation of methylation-silenced tumor-sup-
pressor genes, up-regulation of microRNA and induction of DNA
damage responses [6–10]. DAC achieved marketing authorisation
for the treatment of MDS (approved in the US, based on
randomised study versus best supportive care) and for AML in
older patients (approved in the EU, following randomised
controlled study versus cytarabine or best supportive care)
[3,11,12]. More recently, DAC has shown to be active in the
treatment of very high risk relapsed or refractory AML in children
[13]. Although studies in leukaemic cell lines have suggested
additive effects from combining DAC and Ara-C, the potential
benefit of adding DAC to the multi-agent treatment regimens that
are standard care for AML in children and young adults has not
been explored [14]. Using primary AML samples, we investigated
the most effective scheduling of DAC and Ara-C, both in vitro and
in primary AML xenografts and explored the epigenetic and
transcriptional changes associated with their use.
Methods
Patient Ethics
Paediatric AML bone marrow (BM) cells were obtained from
the Birmingham Children’s Hospital with fully informed written
consent from parents. This study was approved by the Multicentre
Research Ethics Committee, Birmingham Children’s Hospital,
Childhood Cancer and Leukaemic Group (MREC number;
CCLG08/H0405/22).
Cell Culture
Following positive isolation using magnetic cell separation
(Miltenyl Biotec Inc, Germany), 56104 CD34+ blasts were
cultured on MS5 stromal cells and expanded in hematopoietic
media (Myelocult/Stemcell, Grenoble, France) containing 1 mM
hydrocortisone, IL-3, GCSF and TPO (20 ng/ml) (Peprotech,
Rocky Hill, NJ, USA). Following weekly demi-depopulation, long-
term cultures were established from 8 of 11 patient samples as
previously described [15,16].
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Drug Treatment
For growth inhibition assays, primary AML cells were plated at
a density of 56103/mL in 1 mL medium 24 h before treatment.
Cells were treated with serial dilutions of DAC (0.005–50 mM) or
Ara-C (0.001–10 mM) at 0, 24, 48, 72 and 96 h. Cell viability was
measured by trypan blue exclusion and cell proliferation using the
CellTiter96 assay (Promega, Madison, WI, USA). When measur-
ing the half maximal (50%) inhibitory concentration (IC50), fresh
DAC was added every 24 h without changing the medium. The
doses that inhibited proliferation to 50% (IC50) after 120 h of
treatment were analysed using the median-effect method. In
sequential studies using DAC and Ara-C, 5 AML cultures were
treated with the first drug for 5 days followed by the second for 5
more. Cell cycle analysis was performed on treated cells stained
with propidium iodide. DNA and RNA were extracted from cells
using an Allprep kit (Qiagen, Valencia, CA, USA).
Murine Studies
The Birmingham Biomedical Ethics Review Subcommittee
(BERSC) approved all animal protocols in this study. In vivo
experiments were performed on 6–8 week female NOD/Shi-scid/
IL-2Rcnull (NOG) and were carried out in accordance with UK
Home Office Guidelines. Three xenografts were established (36
mice per experiment), using primary paediatric AML patient
samples with different cytogenetic profiles (AML–XG1- FLT3-
ITD mutation with uniparental disomy on chromosome 13;
AML–XG2 - MLL rearrangement; AML–XG3 - translocation 45,
XX). 10–20 weeks following tail vein injection with 7.7-106105
bulk primary cells, the 36 animals were randomised using
GraphPad Software random number generator into 6 groups of
6 mice. Animals were treated with vehicle (PBS), 0.5 mg/kg DAC
or 75 mg/kg Ara-C by intraperitoneal injection either alone or in
combination as set out in Table 1. For the final xenograft
experiment, all animals were treated for 10 days so as to ensure
that all groups had the same duration of treatment. Time to AML
engraftment had previously been established for each sample by
measuring levels of human CD45+/CD33+ cells in the BM from
animals culled at intervals. Following 5 or 10 days of treatment,
depending on the treatment regimen, animals were sacrificed and
single cell suspensions were prepared from the spleen and BM.
Flow cytometry using the BD LSRII was performed on these
samples, which were stained for human CD45 and CD33 and for
mouse CD45 (e-Bioscience, San Diego, CA, USA) and analysed
using FACsDIVA software. The proportion of human cells
(CD45+) which were CD45+CD33+ defined the level of leukaemic
engraftment. Cells from the same treatment groups were pooled
before magnetic isolation of either CD34+ or CD38+ cells
(depending on the leukaemic subset present), and DNA and
RNA extracted as before.
Pyrosequencing Analysis
100 ng of DNA from primary AML cells treated for 5 days with
or without DAC was bisulphite converted using the EZ DNA
methylation kit (Zymo Research, Irvine, CA, USA). 20 ng of
bisulphite modified DNA was used in each PCR and products run
on a Qiagen pyromark system. Pyrosequencing primers were
designed using PSQ primer design software (Qiagen). The PCR
was performed in a total volume of 50 ml using 25 ml hotstart taq
master mix (Thermo Scientific, Waltham, MA, USA), 5 pmol
biotinylated primer, 10 pmol non-biotinylated primer and 10 ml
bisulphite modified DNA. The pyrosequencing reactions were
performed on a Pyromark ID system (Qiagen) and analysed using
Pyro Q-CpG software (Qiagen).
Quantitative PCR (Q-PCR)
mRNA levels following treatment were assayed using Q-PCR.
cDNA was generated from 500 ng of xenograft RNA using the
Superscript III First-strand synthesis system (Invitrogen, Carlsbad,
CA, USA) with random primers (Promega). Q-PCR assays were
prepared in a final volume of 25 ml which contained 1 ml cDNA,
TaqMan universal PCR mastermix (Applied Biosystems, Foster
City, CA, USA), B2M house-keeping assay (Applied Biosystems)
and commercial Taqman assay for target genes; FLT3, MLL5,
CTBP1, ILF3 and MARCKS. Q-PCR assays were performed in
triplicate using an ABI Prism 7700 sequence detection system
(Applied Biosystems). The 2-DD CT method was used to quantify
expression relative to the housekeeping control.
Methylation and Transcriptional Analysis
Infinium Illumina Methylation450 arrays were used to measure
the difference in global DNA methylation between PBS and drug
treated AML xenografts. 1 mg of control and drug treated DNA
was bisulphite converted using the EZ DNA methylation kit
(Zymo Research). Methylation data were normalized and back-
ground subtracted using Genome studio (Illumina, San Diego,
CA, USA). Differentially methylated CpG sites were identified
using Genome Studio; results were filtered to retain CpG in which
the change in beta values between PBS and drug treated samples
was .60.2. Methylation data have been deposited in the Gene
Expression Omnibus under accession number 44830.
Affymetrix U133 Plus 2 microarrays (Affymetrix, Santa Clara,
CA, USA) were used to measure the difference in gene expression
between PBS and drug treated AML xenografts. RNA quality was
tested using a bioanalyzer and hybridized to microarray chips,
which were analysed using the GCOS Software from Affymetrix,
Inc. Probe level quantile normalization and robust multiarray
analysis were performed using the Affymetrix package of the
Bioconductor project. Differentially expressed genes were identi-
fied using Limma analysis with a fold-change threshold of 1.3.
Transcriptional data have been deposited in the Gene Expression
Omnibus under accession number 44857.
Results
Treatment of primary AML cultures
To compare the effect of DAC alone and in combination with
Ara-C, 8 primary AML cultures were established in vitro and
treated daily for 5 days with DAC and Ara-C either as single
agents, in sequence or simultaneously. When administered as a
single agent, Ara-C inhibited proliferation and reduced cell
viability in a dose dependant manner in 7/8 primary AML
Table 1. Xenograft drug schedule.
Week 1 (5 days) Week 2 (5 days)
PBS
DAC alone 0.5 mg/kg
Ara-C alone 75 mg/kg
DAC 0.5 mg/kg with Ara-C
75 mg/kg (D+A)
DAC alone 0.5 mg/kg Ara-C alone 75 mg/kg (D/A)
Ara-C alone 75 mg/kg DAC alone 0.5 mg/kg (A/D)
6 mice in each arm were administered DAC or Ara-C IP in the sequence and
dose shown.
doi:10.1371/journal.pone.0087475.t001
Sequential Administration of DAC and Ara-C in AML
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cultures with IC50s ranging from 0.006 –0.04 mM. The remaining
culture, AML-1, was relatively resistant to treatment with Ara-C
(IC50 53 mM). Similarly, DAC also demonstrated cytotoxic and
anti-proliferative activity against the same panel of primary AML
cultures (IC50s 0.01 –0.06 mM, AML-1 4.5 mM) (Figure 1 and
Table 2).
When selecting the dose of DAC for use in combination with
Ara-C, we aimed to identify that dose which achieved maximum
demethylation in our panel of primary AML cultures. Using
pyrosequencing, we examined the methylation of four candidate
tumour suppressor genes, known to be hypermethylated in
haematological malignancies. We found that in each primary
culture, maximum demethylation was induced following treatment
with 0.05 mM DAC; however, the level of demethylation achieved
with this dose of DAC differed across the panel of AML samples,
and did not correspond to the IC50 (Figure 2).
We next explored the effect of low dose DAC treatment
(0.05 mM) combined with the sample-specific IC50 dose of Ara-C,
on 5/8 AML primary cultures for which sufficient cell number
Figure 1. The in vitro effects of DAC and Ara-C in primary paediatric AML. A). Changes in viability following treatment with DAC or Ara-C at a
range of concentrations in 8 primary AML patient samples. B) Changes in proliferation following treatment with DAC or Ara-C at the IC50 dose in 8
primary AML patient cultures. Cells were treated at 0, 24, 48, 72 and 96 h, both cell viability and proliferation were measured at 120 h. All experiments
were performed in triplicate.
doi:10.1371/journal.pone.0087475.g001
Table 2. IC50 dose following treatment with DAC and Ara-C
alone.
DAC IC50 Ara-C IC50
AML-1 4.5 mM 53 mM
AML-2 0.04 mM 0.008 mM
AML-3 0.03 mM 0.007 mM
AML-4 0.04 mM 0.03 mM
AML-5 0.02 mM 0.04 mM
AML-6 0.06 mM 0.01 mM
AML-7 0.01 mM 0.02 mM
AML-8 0.04 mM 0.006 mM
Cells were treated at 0, 24, 48, 72 and 96 h and the IC50 measured at 120 h.
doi:10.1371/journal.pone.0087475.t002
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were available. We showed that both sequential and simultaneous
administration of DAC and Ara-C induced a greater decrease in
cell viability than either drug alone. When the drugs were
administered sequentially, the decrease in viability was greatest
when cells were treated with DAC for 5 days followed by Ara-C
for 5 days in 4/5 samples tested. In the remaining sample, AML-3,
the decrease was greater when Ara-C was followed by DAC
(Figure 3A). Cell cycle analysis following treatment of primary
AML cultures with DAC and Ara-C at the concentrations
described above, revealed a decrease in the proportion of cells in
G0/G1 phase and an increase in the proportion of cells in G2/M
phase. Both sequential and simultaneous treatment resulted in a
depletion of cells in G0/G1 phase and an increase in apoptotic
cells; treatment with DAC followed by Ara-C caused the greatest
increase in apoptosis (Figure 3B).
Treatment of AML xenografts
We next examined the impact of DAC and Ara-C alone or in
combination, on human AML blast cell survival in three primary
paediatric AML xenografts according to the schedules set out in
Table 1. Two of these xenografts were established using those
samples which had shown the greatest decrease in methylation
following DAC treatment in vitro (AML-6, AML-XG1 and AML-
7, AML-XG2). The remaining xenograft was established using a
sample which had shown little methylation change when treated
with DAC in primary culture but had shown the greatest change
in cellular proliferation following DAC treatment in vitro (AML-4,
AML-XG3). The endpoint of these experiments was the level of
BM engraftment human CD45+/CD33+ at a fixed time point
following one cycle of treatment. Notably, treatment with Ara-C
or DAC alone or when administered simultaneously did not
reduce the proportion of human CD45+/CD33+ BM engraftment
compared to PBS controls in any of the three xenografts. In
contrast, sequential administration of Ara-C and DAC induced a
significant decrease in these cell populations when compared to
both PBS controls and Ara-C alone (Figure 4A and B). It is
conceivable that the decrease observed in the first two xenograft
experiments (AML-XG1 and AML-XG2), was a result of
sequential treatment being delivered for 10 days whereas the
DAC and Ara-C alone groups were treated for 5 days. However, a
significant decrease was observed in the final xenograft experiment
when the DAC and Ara-C alone groups were also treated for 10
days. DAC and Ara-C injected as single agents and in
combination were well tolerated following days of treatment, with
,10% weight loss observed in those animals given a second week
of treatment. In the single xenograft (AML-XG1) in which splenic
AML engraftment was observed, the proportion of human
CD45+/CD33+ cells in the spleen were significantly lower in all
treatment groups when compared with controls (Figure 4C).
Genome-wide expression and methylation profiling
DNA methylation and gene expression profiling were per-
formed on AML blasts from all three xenografts following
treatment with PBS, DAC, Ara-C, or both, delivered either
sequentially or simultaneously. Pyrosequencing was used to
validate methylation changes at selected CpG sites and Q-PCR
Figure 2. Pyrosequencing analysis of 4 tumour suppressor genes following DAC treatment. Changes in methylation status of a CpG site
for 4 representative candidate genes (CSMD1, RARB, CADM1 and CDH13), following treatment with DAC at a range of concentrations in 8 primary
AML patient cultures. Cells were treated at 0, 24, 48, 72 and 96 h, DNA methylation was measured at 120 h. All experiments were performed in
duplicate.
doi:10.1371/journal.pone.0087475.g002
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used to validate changes in concordantly regulated candidate
genes, some of which are known to be associated with reduced cell
proliferation, invasion and survival in AML or other tumour types
(Figure 5).
DNA methylation profiling revealed that less than 4% of all
CpG sites were changed with DAC treatment alone, whereas
approximately a third of all CpG sites were changed following
either of the sequential treatments. The ratio of hypomethylation
to hypermethylation changes also differed dependent on the drug
treatment schedule. While DAC was almost exclusively a
hypomethylating agent in all xenografts, treatment schedules that
included Ara-C were associated with a greater proportion of
hypermethylation changes. Interestingly, both hypermethylation
and hypomethylation changes were less pronounced when Ara-C
and DAC were given simultaneously (Table 3).
Hypomethylation changes following treatment with any drug
combination, were most common at CpG sites which had high
beta values (high level methylation) in control-treated cells, and
irrespective of the regimen used, hypomethylation occurred more
commonly in gene bodies than in CpG sites closer to transcrip-
tional start sites. In contrast, hypermethylation changes following
treatment with any drug combination were most common at CpG
sites which had low beta values (low level methylation) in control-
treated cells and occurred more frequently at transcriptional start
sites (Figure S1, Table S1). Although extensive DNA methylation
changes were observed with all drug combinations tested, the
overlap between the top 1000 concordantly changed CpG sites
across the three xenografts was small (Figure S2).
Genome wide profiling revealed a substantial number of
transcriptional changes following drug treatment of each xenograft
(Table S2). However, for each drug treatment, the number of
genes concordantly changed across the three xenografts was small
and these common transcriptional changes were unique to that
treatment (Figure S3, Table S3). However, within each xenograft
there was a modest but significant overlap in the transcriptional
changes induced following sequential treatments, Ara-C followed
by DAC and DAC followed by Ara-C (Figure S4).
Discussion
Our results support previous studies showing that low doses of
DAC have both cytotoxic and anti-proliferative effects on primary
AML samples in vitro and are associated with DNA demethylation
[17–19]. Our in vitro and in vivo data are also consistent with
clinical reports indicating that low dose DAC is an active agent in
the treatment of AML [11,13]. However, our most compelling
observation is the substantially increased anti-leukemia effect when
DAC is given sequentially with Ara-C compared to when DAC
and Ara-C were given alone. This effect could not be attributed to
the longer duration of the sequential treatment which was
Figure 3. The in vitro effects of DAC and Ara-C in combination in primary paediatric AML. A) The percentage of viable cells following
treatment with each drug regimen compared to PBS controls in 5 primary AML patient cultures (* P,0.01). All experiments were performed in
triplicate. B) The percentage of cells in each phase of cell cycle following treatment with each drug regimen, for a representative primary AML sample
(AML-7). All experiments were performed in duplicate.
doi:10.1371/journal.pone.0087475.g003
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delivered for 10 days compared to the DAC and Ara-C alone
groups which were treated for 5 days because a significant
decrease was observed in the final xenograft experiment when the
DAC and Ara-C alone groups were also treated for 10 days. We
have shown using AML xenografts that low dose DAC when given
sequentially with Ara-C, regardless of the schedule has a
substantially increased anti-leukemia effect compared to Ara-C
alone.
Consistent with recent reports we confirmed using genome-wide
methylation profiling that DAC is an effective demethylating agent
when used to treat AML cells and that demethylation is more
likely to occur at CpG sites which are heavily methylated ab initio
[17]. Although the number of CpG sites demethylated following
treatment with Ara-C was 10 times greater than that observed
following DAC we found that Ara-C, unlike DAC frequently
induces hypermethylation changes which is consistent with
previous reports of AraC’s epigenetic modulating activity
[20,21]. Simultaneous treatment with Ara-C and DAC resulted
in substantially fewer hypomethylation and hypermethylation
changes than were seen with use of either drug alone whereas
sequential treatment resulted in substantially more. Consistent
with our finding that sequential treatment was found to be
effective in reducing tumour burden irrespective of the order in
which these agents were administered, there was a significant and
substantial overlap in the transcriptional changes observed in the
same xenograft following treatment with DAC followed by Ara-C
and Ara-C followed by DAC. However, the absence of any
methylation or transcriptional overlap between xenografts follow-
Figure 4. The in vivo effects of DAC and Ara-C in primary paediatric AML xenografts. A and B) Cells isolated from BM of three xenografts
following 5 or 10 days of treatment were stained for human CD45 and CD33 and for mouse CD45; the proportion of human cells which were
CD45+CD33+ from each treatment group were compared to Ara-C treatment alone in the BM. C) Cells isolated from the spleen which were human
CD45+CD33+ compared to PBS (* P ,0.001).
doi:10.1371/journal.pone.0087475.g004
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ing treatment with these sequential regimens may reflect the
variability in their cytogenetic profiles. Given our small sample size
and the absence of a xenograft that did not respond to sequential
treatment, we were unable to identify predictive markers of drug
response.
While we were unable to provide a mechanistic explanation for
the benefits of combined sequential treatment, we were able to
show using genome-wide methylation and expression profiling that
‘‘epigenetic priming’’ which is often advanced as a justification for
combining cytotoxic agents with a demethylating agent is an
implausible explanation for the beneficial effects of combined
therapy observed in this study. It is likely that these issues will only
be adequately addressed in the context of a clinical trial in which
samples are prospectively collected from a cohort of responding
and non-responding patients. Our findings lend critical weight to
the need for clinical studies evaluating the use of combined
therapy in paediatric AML patients.
Figure 5. Q-PCR analysis of candidate genes identified from the expression arrays. Changes in the expression of 5 genes which were
concordantly de-regulated in all three xenografts following sequential treatment with either Ara-C followed by DAC (ILF3 and MARCKS) or DAC
followed by Ara-C (FLT3, CTBP1 and MLL5). Assays were carried out in triplicate.
doi:10.1371/journal.pone.0087475.g005





% of total CpG







PBS vs DAC 17275 3.8 17258 17 1015:1 20.032
PBS vs Ara-C 122690 26.4 85702 36988 2:1 0.025
PBS vs D+A 9906 2.0 5223 4683 1:1 0.015
PBS vs A/D 164220 34.4 156585 7635 21:1 20.028
PBS vs D/A 162719 35.7 123987 38732 3:1 20.064
AML - XG2
PBS vs DAC 14879 3.0 14857 22 675:1 20.042
PBS vs Ara-C 156544 33.3 118532 38012 3:1 0.04
PBS vs D+A 12809 2.8 9611 3198 3:1 0.0255
PBS vs A/D 111255 22.9 102419 8836 12:1 20.047
PBS vs D/A 170595 35.8 110686 59909 2:1 20.078
AML - XG3
PBS vs DAC 10304 2.2 10290 14 735:1 20.0485
PBS vs Ara-C 137804 28.9 84792 53012 2:1 0.011
PBS vs D+A 8831 1.9 3433 5398 1:1 0.005
PBS vs A/D 99420 21.3 93227 6193 15:1 20.0195
PBS vs D/A 204784 43.2 143348 61436 2:1 20.092
For each xenograft, the number of hypomethylation and hypermethylation changes as well as the median change in beta value following treatment with each drug
regimen. Differentially methylated CpG sites were identified using Genome Studio; results were filtered to retain CpG in which the change in beta values between PBS
and drug treated samples was .60.2.
doi:10.1371/journal.pone.0087475.t003
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Supporting Information
Figure S1 Change in methylation values upon treatment with
different drug regimens, versus methylation in mock-treated
samples, for a representative primary AML sample (AML-XG1).
(TIF)
Figure S2 Number of concordant changes in methylation
following treatment with each drug regimen. Results for both
hypermethylation and hypomethylation changes are shown. There
was no overlap for CpG sites hypermethylated following treatment
with DAC alone.
(TIF)
Figure S3 Number of concordantly regulated genes across the
three xenografts following treatment with each drug regimen.
(TIF)
Figure S4 Concordantly regulated genes following sequential
treatment within the same xenograft.
(TIF)
Table S1 Methylation changes across different regions of the
genome following treatment with different drug regimens. The
frequency with which methylation changes were found at different
locations in a xenograft following treatment based on the Illumina
gene annotation (TSS1500, TSS200, 59UTR, 1st Exon, gene body
and 39UTR).
(TIF)
Table S2 Summary of transcriptional changes following treat-
ment with different drug regimens. For each xenograft, the
number of up-regulated and down-regulated genes is shown.
(TIF)
Table S3 List of genes concordantly regulated following
treatment with each drug regimen.
(XLSX)
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